Legend Biotech annual free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Legend Biotech Free Cash Flow (FCF) History (LEGN)
Legend Biotech reported −$128.8M in free cash flow for fiscal 2025, an increase of $29.3M from the previous fiscal year, with a free cash flow margin of −12.52%.
View full Legend Biotech company overviewLegend Biotech free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$128.8M | $29.3M | — | −12.52% |
| 2024 | 2024-12-31 | −$158.1M | $255.3M | — | −25.21% |
| 2023 | 2023-12-31 | −$413.4M | −$191.2M | — | −144.98% |
| 2022 | 2022-12-31 | −$222.2M | $18.5M | — | −189.91% |
| 2021 | 2021-12-31 | −$240.7M | $8.6M | — | −349.67% |
| 2020 | 2020-12-31 | −$249.3M | −$139.4M | — | −332.35% |
| 2019 | 2020-01-01 | −$109.8M | −$396.6M | — | −183.12% |
| 2018 | 2018-12-31 | $286.7M | — | — | +583.57% |
Legend Biotech quarterly free cash flow
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | −$24.6M | $59.8M | — | −8.02% |
| Q3 2025 | 2025-09-30 | $23.8M | $101.7M | — | +8.74% |
| Q2 2025 | 2025-06-30 | −$22.3M | −$17.2M | — | −8.73% |
| Q1 2025 | 2025-03-31 | −$105.8M | −$115.0M | — | −54.22% |
| Q4 2024 | 2024-12-31 | −$84.4M | $15.6M | — | −45.26% |
| Q3 2024 | 2024-09-30 | −$77.9M | −$11.7M | — | −48.62% |
| Q2 2024 | 2024-06-30 | −$5.1M | $98.6M | — | −2.72% |
| Q1 2024 | 2024-03-31 | $9.3M | $152.8M | — | +9.87% |
| Q4 2023 | 2023-12-31 | −$100.0M | −$25.3M | — | −125.88% |
| Q3 2023 | 2023-09-30 | −$66.2M | — | — | −68.98% |
| Q2 2023 | 2023-06-30 | −$103.7M | — | — | −141.36% |
| Q1 2023 | 2023-03-31 | −$143.5M | — | — | −394.89% |
| Q3 2022 | 2022-09-30 | −$74.7M | — | — | −272.98% |
Legend Biotech free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$249.3M to −$128.8M, a net increase of $120.5M. Legend Biotech's latest reported quarter, Q4 2025, generated −$24.6M in free cash flow, an increase of $59.8M year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Legend Biotech filings at SEC.gov ↗